Alnylam Pharmaceuticals Inc. (Nasdaq: ALNY) is buying Sirna Therapeutics Inc. from Merck & Co. Inc. (NYSE: MRK) for $175 million, and separately received a $700 million equity investment from Genzyme.

Sirna Therapeutics, headquartered in San Francisco, develops drugs that aim to suppress diseases from genes.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.